ACAD Stock-Based Compensation
Acadia Pharmaceuticals Inc · Stock-Based Compensation
ACAD Stock-Based Compensation
Latest reported$59.52Mperiod ending
ACAD TTM Stock-Based Comp ($2.36B → $59.52M)
TTM stock-based compensation
High-resolution chart · PNG
ACAD stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 59,516,000 | |
| 42,218,000 | |
| 38,900,000 | |
| 49,350,000 | |
| 62,334,000 | |
| 63,679,000 | |
| 67,049,000 | |
| 74,622,000 | |
| 66,997,000 | |
| 66,466,000 | |
| 66,421,000 | |
| 62,812,000 | |
| 62,585,000 | |
| 67,943,000 | |
| 68,201,000 | |
| 66,667,000 | |
| 63,901,000 | |
| 65,394,000 | |
| 63,615,000 | |
| 71,930,000 | |
| 77,756,000 | |
| 75,258,000 | |
| 84,422,000 | |
| 82,990,000 | |
| 83,815,000 | |
| 84,730,000 | |
| 82,265,000 | |
| 82,903,000 | |
| 80,875,000 | |
| 81,005,000 | |
| 81,564,000 | |
| 83,182,000 | |
| 82,711,000 | |
| 80,403,000 | |
| 75,532,000 | |
| 68,931,000 | |
| 63,242,000 | |
| 58,881,000 | |
| 55,265,000 | |
| 48,749,000 | |
| 44,005,000 | |
| 37,621,000 | |
| 40,194,000 | |
| 35,937,000 | |
| 30,573,000 | |
| 27,405,000 | |
| 16,039,000 | |
| 13,568,000 | |
| 11,558,000 | |
| 8,291,000 | |
| 5,711,000 | |
| 4,088,000 | |
| 2,685,000 | |
| 2,099,000 | |
| 1,930,000 | |
| 1,787,000 | |
| 1,700,000 | |
| 1,636,000 | |
| 1,598,000 | |
| 1,526,000 | |
| 1,518,000 | |
| 1,477,000 | |
| 1,583,000 | |
| 1,579,000 | |
| 1,797,000 | |
| 2,040,000 | |
| 2,134,000 | |
| 4,789,000 | |
| 4,178,000 | |
| 3,562,000 | |
| 3,823,000 | |
| 5,131,000 | |
| 5,131,000 | |
| 5,131,000 | |
| 5,569,000 | |
| 4,652,000 | |
| 4,652,000 | |
| 4,652,000 | |
| 903,378,000 | |
| 2,207,700,000 | |
| 2,207,700,000 | |
| 2,207,700,000 | |
| 1,678,900,000 | |
| 2,727,000,000 | |
| 2,727,000,000 | |
| 2,727,000,000 | |
| 2,355,800,000 |